BioCryst Pharmaceuticals Inc (BCRX)vsTeva Pharma Industries Ltd ADR (TEVA)
BCRX
BioCryst Pharmaceuticals Inc
$8.12
-2.05%
HEALTHCARE · Cap: $2.25B
TEVA
Teva Pharma Industries Ltd ADR
$37.09
+2.04%
HEALTHCARE · Cap: $42.84B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 1741% more annual revenue ($17.32B vs $940.61M). TEVA leads profitability with a 4.1% profit margin vs -40.9%. TEVA appears more attractively valued with a PEG of 0.67. BCRX earns a higher WallStSmart Score of 55/100 (C-).
BCRX
Buy55
out of 100
Grade: C-
TEVA
Hold49
out of 100
Grade: D+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 45.1%
Revenue surging 33.6% year-over-year
Earnings expanding 1400.0% YoY
Conservative balance sheet, low leverage
Earnings expanding 72.2% YoY
Growing faster than its price suggests
Areas to Watch
Expensive relative to growth rate
ROE of -1925.0% — below average capital efficiency
Distress zone — elevated risk
Currently unprofitable
4.1% margin — thin
Operating margin of 4.0%
Premium valuation, high expectations priced in
Revenue declined 0.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : BCRX
The strongest argument for BCRX centers on Operating Margin, Revenue Growth, EPS Growth. Revenue growth of 33.6% demonstrates continued momentum.
Bull Case : TEVA
The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.67 suggests the stock is reasonably priced for its growth.
Bear Case : BCRX
The primary concerns for BCRX are PEG Ratio, Return on Equity, Altman Z-Score.
Bear Case : TEVA
The primary concerns for TEVA are Profit Margin, Operating Margin, P/E Ratio. A P/E of 61.3x leaves little room for execution misses. Debt-to-equity of 2.18 is elevated, increasing financial risk.
Key Dynamics to Monitor
BCRX profiles as a hypergrowth stock while TEVA is a value play — different risk/reward profiles.
TEVA carries more volatility with a beta of 0.87 — expect wider price swings.
BCRX is growing revenue faster at 33.6% — sustainability is the question.
TEVA generates stronger free cash flow (307M), providing more financial flexibility.
Bottom Line
BCRX scores higher overall (55/100 vs 49/100) and 33.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BioCryst Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small molecule drugs. The company is headquartered in Durham, North Carolina.
Visit Website →Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?